June 18, 2020 08:54 AM EDT
Deals

Ab­b­Vie beefs up the im­munol­o­gy pipeline, bet­ting up to $865M on a PhII-ready drug — and fu­el­ing a biotech stock fren­zy

John Carroll

Editor & Founder

Ab­b­Vie’s im­munol­o­gy team is toss­ing $60 mil­lion in­to the pot be­ing wa­gered on the lead drug at Mitch Gold’s lat­est ven­ture.

The Den­dreon founder …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times